期刊文献+

无细胞耻垢分枝杆菌疫苗对豚鼠的长期毒性研究 被引量:1

Evaluation of long-term toxicity for Mycobacterium smegmatis vaccine in guinea pigs
下载PDF
导出
摘要 目的:观察无细胞耻垢分枝杆菌疫苗对豚鼠的长期毒性。方法:48只豚鼠随机均分成无细胞耻垢分技杆菌疫苗低、中、高剂量组(疫苗用量分别为50,250和500μg·kg-1)和阴性对照组,每周1次,连续7周肌内注射疫苗,阴性对照组给予等体积的生理氯化钠溶液。在实验前、中、末期(n=12)和恢复期(n=4)观察动物体重、白蛋白和球蛋白比值、抗疫苗抗体IgG和总IgE的含量;在实验末期和恢复期对豚鼠作病理组织学检查和骨髓细胞学检查。结果:阴性对照组豚鼠抗疫苗抗体IgG始终为阴性,疫苗组豚鼠注射疫苗后抗疫苗抗体IgG阳转;各组豚鼠在整个实验过程中体重稳定增加,白蛋白和球蛋白比值未见明显改变,血清IgE均为阴性;各脏器未见病理性损害和免疫复合物沉积,各脏器系数与阴性对照组比较未见统计学差异;骨髓各系造血细胞未见抑制现象。结论:无细胞耻垢分枝杆菌疫苗对豚鼠无长期毒性。 Objective:To assess the long-term immunotoxicology for Myeobacterium smegmatis vaccine in guinea pigs. Methods: 48 guinea pigs were randomized to intramuscularly inject low, middle or higher dose of Mycobacterium smegmatis vaccine (50,250 and 500μg·kg^-1) or normal saline alone as control once a week for 7 weeks. The effect was assessed based on the changes of body weight, ratio of albumin to globin, IgG against vaccine, and total IgE pre, during, at the end and post dosing. The histopathological and marrow cytological examinations of the guinea pigs were performed at the end of the dosing and in the recovery period. Results: The guinea pigs as control had negative IgG at all. The guinea pigs administering the three doses of vaccine turned the positive IgG and negative total IgE after immunization and had normal weight gain. The ratios of albumin to globin showed no significant changes. No histological lesions and immunological complex deposits were observed. No statistical difference of organ coefficient was found between control group and vaccine groups. No repression for hematopoietic cells in the marrow occurred. Conclusion: The Mycobacterium smegmatis vaccine has no long-term toxicity in guinea pigs.
出处 《中国新药杂志》 CAS CSCD 北大核心 2006年第19期1640-1643,共4页 Chinese Journal of New Drugs
基金 国家"863"项目(2004AA2Z3451)
关键词 耻垢分枝杆菌疫苗 长期毒性 豚鼠 Mycobacterium smegmatis vaccine long-term toxicity guinea pigs
  • 相关文献

参考文献5

  • 1王国治,徐苗,陈保文,等.耻垢分枝杆菌菌苗:中国,ZL 02130687.7[P].2006-01.
  • 2佘佳红,袁伯俊,陆国才,胡振林,陈黛影.乙肝核酸疫苗安全性的初步研究[J].中国新药杂志,2005,14(9):1141-1144. 被引量:1
  • 3FRANCOIS V. Non-clinical vaccine safety assessment [ J]. Toxicology, 2002,174 ( 1 ) : 37 - 43.
  • 4国家药品食品监督管理局药品审评中心.预防用生物制品临床前安全性评价技术审评一般原则[EB/OL].[2005—12—08].http://www. cde. org. cn/page/framelimit. cbs? ResName = dzkw.
  • 5KUMAGAI T, OZAKI T, KAMADA M, et al. Gelatin-containing diphtheria-tetanus-pertussi (DTP)vaccine causes sensitization to gelatin in the recipients[ J ]. Vaccine ,2000,18 ( 15 ) : 1555 - 1561.

二级参考文献6

  • 1Saul A, Lawrence G, Smillie A, et al. Human phase I vccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant[J]. Vaccine, 1999,17(24) :3145 - 3159.
  • 2Ivhncini M, Hadchouel M, Davis HL. et al. DNA-mediated immunization in transgenic mouse model of the hepatitis B surface antigen chronic carrier state[J].Proc Natl Acad Sci USA, 1996,93(22) : 12496 - 501.
  • 3Prince AM. Successful nucleic acid based immunization of new born chimpanzees against hepatitis B virus [ J ]. Vaccine, 1997, 15 ( 8 ) :916.
  • 4Mor G, Klinman DM. Do DNA vaccine induce autoimmune disease?[J]. Human Gene Therapy, 1997,8(7) :293.
  • 5Martin T, Parker SE. Plasmid DNA malaria vaccine: the potential for genomic interaction after intramuscular injection[J] . Human Gene Therapy, 1999,10(6) : 759.
  • 6秦山,赵连三,范红,何芳,雷学忠,刘丽.乙肝核酸疫苗NV-HB/s接种小鼠的免疫反应[J].华西医科大学学报,2002,33(4):497-500. 被引量:5

共引文献3

同被引文献9

  • 1叶隆昌,陈保文,朱永东,徐苗,刘林飞,沈小兵,左于会,苏城,王兆军,殷玉和,汪华,马玉杰,张远涛,王国治,许卫国.无细胞耻垢分枝杆菌疫苗的Ⅰ期临床研究[J].中国新药杂志,2007,16(7):565-568. 被引量:10
  • 2Lalvani A, Nagvenkar P, Udwadia Z, et al. Enumeration of T cells specific for RDI-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis, 2001, 183 (3): 469-477.
  • 3Hanifa Y, Grant AD, Lewis J, et al. Prevalence of latent tuberculosis infection among gold miners in South Africa. Int J Tuberc Lung Dis, 2009, 13 (1): 39-46.
  • 4谢惠安,阳国太,林善梓,等.现代结核病学.1版,北京:人民卫生出版社,2002:153-154.
  • 5Mayo RE, Stanford JL.Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Attica, 1991-97. Trans R Soc Trop Med Hyg, 2000, 94 (5): 563-568.
  • 6Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci, 2004, 9: 1701-1719.
  • 7王国治,徐苗,陈保文,等.耻垢分枝杆菌菌苗:中国,ZL 02130687.7[P].2006-01.
  • 8屠德华.结核病预防措施[J].中国社区医师,2008,24(1):14-16. 被引量:3
  • 9全国结核病流行病学抽样调查技术指导组.2000年全国结核病流行病学抽样调查报告[J].中国防痨杂志,2002,24(2):65-108. 被引量:1376

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部